GENTAMICIN SULFATE CREAM USP, 0.1% - gentamicin sulfate cream

Manufacturer
Dispensing Solutions, Inc. | PSS World Medical, Inc.
Effective date
2012-10-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:15:59

Label at a glance#

ProductGentamicin Sulfate
Active ingredientGENTAMICIN SULFATE
Label structure10 sections

Indications and uses

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Ge...

Dosage and administration

A small amount of gentamicin sulfate cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. I...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For Dermatologic Use Only

Not For Ophthalmic Use

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Gentamicin Sulfate Cream is a wide spectrum antibiotic preparation for topical administration. Each gram contains Gentamicin Sulfate USP equivalent to 1 mg gentamicin base in a cream base containing stearic acid, propylene glycol monostearate, isopropyl myristate, polysorbate 40, propylene glycol, sorbitol solution and purified water with methylparaben and butylparaben as preservatives.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Cream usually clears the lesions promptly. In secondary skin infections, Gentamicin Sulfate Cream aids in the treatment of the underlying dermatoses by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Kiebsiella pneumoniae.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin sulfate cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin sulfate cream has been used successfully in infants over one year of age, as well as in adults and children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In patients with dermatoses treated with gentamicin sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with gentamicin sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of gentamicin sulfate followed by exposure to ultraviolet radiation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of gentamicin sulfate cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gentamicin Sulfate Cream USP, 0.1% is supplied in 15 gram tubes NDC 55045-1147-05.

Store at controlled room temperature 15°-30°C (59°-86°F).

Package Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 55045-1147-05

FOUGERA®

GENTAMICIN SULFATE
CREAM USP, 0.1%

Rx only

FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.

Each gram contains Gentamicin Sulfate USP equivalent to 1 mg gentamicin base in a cream base containing stearic acid, propylene glycol monostearate, isopropyl myristate, polysorbate 40, propylene glycol, sorbitol solution and purified water with methylparaben and butylparaben as preservatives.

NEW WT 15 grams

NDC 55045-1147-05NDC 55045-1147-05

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197735gentamicin sulfate 0.1 % Topical CreamPSN3
197735gentamicin 1 MG/ML Topical CreamSCD3
197735gentamicin (as gentamicin sulfate) 0.1 % Topical CreamSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
GENTAMICIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
3b7b3a7a-635f-32a3-0c6c-7ad028e3de91Product name220250107
43025f0d-698c-68da-cec9-ea4261a7ef7aProduct name220250107
d3946667-8212-d1f2-67e1-5643a329bb56Product name220200403
4ce5dce5-e8a7-e4f6-0059-b527e4307477Product name220190501
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
55045-1147-52019-11-27C16284748780-19855d018-d334-cd31-e053-dbdaa90ab51aGENTAMICIN SULFATE CREAM USP, 0.1% - gentamicin sulfate cream

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
55045-1147-5Gentamicin Sulfate15 g in 1 TUBECREAM153

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
55045-1147GENTAMICIN SULFATE CREAM [DISPENSING SOLUTIONS, INC.]3Legacy NDC, 1 package rows20121003_e673c84f-d3cc-4e61-bdc7-5679cde9f359.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
GENTAMICIN SULFATEACTIVE INGREDIENT8X7386QRLV3
GENTAMICINACTIVE MOIETYT6Z9V48IKG3
BUTYLPARABENINACTIVE INGREDIENT3QPI1U3FV83
ISOPROPYL MYRISTATEINACTIVE INGREDIENT0RE8K4LNJS3
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T3
POLYSORBATE 40INACTIVE INGREDIENTSTI11B5A2X3
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V33
PROPYLENE GLYCOL MONOPALMITOSTEARATEINACTIVE INGREDIENTF76354LMGR3
SORBITOLINACTIVE INGREDIENT506T60A25R3
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65AP3
WATERINACTIVE INGREDIENT059QF0KO0R3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
55045-114755045-1147-5
0168-0071

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 5 · 276 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / PARENTERAL18 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / VAGINAL0.1 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APAEROSOL, FOAM / TOPICAL8 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOL MONOPALMITOSTEARATEPROPYLENE GLYCOL MONOPALMITOSTEARATEF76354LMGRCREAM / TOPICAL9.3 %w/wExact identifier — unii candidate
6 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCONCENTRATE / ORAL600 mg/1mlExact identifier — unii candidate
44 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RTABLET / ORAL337.28 mgExact identifier — unii candidate
44 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APEMULSION / ORALNAExact identifier — unii candidate
26 equally ranked IID candidates
POLYSORBATE 40POLYSORBATE 40STI11B5A2XELIXIR / ORAL0.05 mg/5mlExact identifier — unii candidate
7 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSGEL / TOPICAL29 mgExact identifier — unii candidate
18 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET / SUBLINGUAL9 mgExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / VAGINAL1225 mgExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RINJECTION, SOLUTION / INTRAVENOUS4050 mgExact identifier — unii candidate
44 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APAEROSOL, FOAM / VAGINAL4 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSYSTEM / TOPICAL6300 mgExact identifier — unii candidate
44 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, METERED / RECTALNAExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / RECTAL3315 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSHAMPOO, SUSPENSION / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, COATED / ORAL16 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LIQUID / RESPIRATORY (INHALATION)10 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / SUBCUTANEOUS1.4 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION, EXTENDED RELEASE / ORAL1000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAVENOUS4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY, METERED / NASAL240 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, EXTENDED RELEASE / ORAL0.17 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RINJECTION / INTRAMUSCULARNAExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGRANULE, FOR SUSPENSION / ORAL80 mgExact identifier — unii candidate
79 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSLOTION / TOPICAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TENEMA / RECTAL0.18 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGEL / TOPICAL24 mgExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RPOWDER, FOR SUSPENSION / ORAL12000 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAMUSCULAR7459 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, EXTENDED RELEASE / TRANSDERMAL58.13 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TAEROSOL, FOAM / TOPICAL0.16 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APPELLET / SUBCUTANEOUS0.97 mgExact identifier — unii candidate
26 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8LOTION / TOPICAL4 mgExact identifier — unii candidate
15 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSSUSPENSION / AURICULAR (OTIC)0.02 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, SOLUBLE / BUCCAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET, FILM COATED / ORAL176 mgExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3ELIXIR / ORAL9306 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS15 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / ORAL27120 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RTABLET, COATED / ORAL12.96 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / OPHTHALMIC0.44 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RTABLET, EXTENDED RELEASE / ORAL428 mgExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRA-ARTICULAR0.24 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPOWDER, FOR SOLUTION / ORAL126 mgExact identifier — unii candidate
79 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET / BUCCAL6 mgExact identifier — unii candidate
26 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8LIQUID / TOPICAL0.02 %w/wExact identifier — unii candidate
15 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, CHEWABLE / ORAL1.28 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT, AUGMENTED / TOPICAL714 mgExact identifier — unii candidate
81 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8SUSPENSION / ORAL12 mgExact identifier — unii candidate
15 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRAMUSCULAR95 mgExact identifier — unii candidate
79 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET, ORALLY DISINTEGRATING / ORAL10 mgExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED, EXTENDED RELEASE / ORAL19 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAMUSCULAR0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062531-001GENTAMICIN SULFATEGENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0584e616aacf4f…
2026-08-18 06:07:402026-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-052680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-051e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-058072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-054b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0587673890dc5c…
2021-03-12 10:30 UTC2021-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-058869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053f01610625f2…
2019-09-15 20:21 UTC2019-09A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05b00525d2431f…
2019-07-19 19:46 UTC2019-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-056a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-051c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-059b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053f0d92c62455…
2023-05-13 08:27 UTC2023-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05053a50430f4f…
2023-01-26 05:58 UTC2023-01A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
cca757b4-55c2-4d0f-b578-e4d658c6db2fe673c84f-d3cc-4e61-bdc7-5679cde9f3592012-10-02Adverse reactionsExact identifier
spl id: cca757b4-55c2-4d0f-b578-e4d658c6db2f
spl set id: e673c84f-d3cc-4e61-bdc7-5679cde9f359

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.